563 related articles for article (PubMed ID: 20797569)
1. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
2. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
Vaziri ND
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F262-72. PubMed ID: 16403839
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome and renal failure: similarities and differences.
Kaysen GA
Panminerva Med; 2006 Sep; 48(3):151-64. PubMed ID: 17122751
[TBL] [Abstract][Full Text] [Related]
5. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral contraceptives on lipid metabolism.
Krauss RM
J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
[TBL] [Abstract][Full Text] [Related]
7. Disorders in high-density metabolism with insulin resistance and chronic kidney disease.
Kaysen GA
J Ren Nutr; 2007 Jan; 17(1):4-8. PubMed ID: 17198924
[TBL] [Abstract][Full Text] [Related]
8. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats.
Joles JA; van Goor H; van der Horst ML; van Tol A; Elema JD; Koomans HA
Lab Invest; 1995 Dec; 73(6):912-21. PubMed ID: 8558854
[TBL] [Abstract][Full Text] [Related]
9. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
Staprans I; Pan XM; Rapp JH; Feingold KR
Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
[TBL] [Abstract][Full Text] [Related]
10. Statins and renal diseases: from primary prevention to renal replacement therapy.
D'Amico G
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
12. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy in patients with chronic kidney disease: to use or not to use.
Steinmetz OM; Panzer U; Stahl RA; Wenzel UO
Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.
Seiler S; Schlitt A; Jiang XC; Ulrich C; Blankenberg S; Lackner KJ; Girndt M; Werdan K; Buerke M; Fliser D; Heine GH
Nephrol Dial Transplant; 2008 Nov; 23(11):3599-604. PubMed ID: 18503096
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein function recent advances.
Ansell BJ; Watson KE; Fogelman AM; Navab M; Fonarow GC
J Am Coll Cardiol; 2005 Nov; 46(10):1792-8. PubMed ID: 16286161
[TBL] [Abstract][Full Text] [Related]
17. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.
Malle E; Marsche G; Panzenboeck U; Sattler W
Arch Biochem Biophys; 2006 Jan; 445(2):245-55. PubMed ID: 16171772
[TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory properties of HDL.
Barter PJ; Nicholls S; Rye KA; Anantharamaiah GM; Navab M; Fogelman AM
Circ Res; 2004 Oct; 95(8):764-72. PubMed ID: 15486323
[TBL] [Abstract][Full Text] [Related]
19. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
Bakir R; Hilliquin P
Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
[TBL] [Abstract][Full Text] [Related]
20. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
Kes P; Reiner Z; Brunetta B
Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
